Chris Howerton
Stock Analyst at Jefferies
(1.76)
# 2,105
Out of 4,667 analysts
74
Total ratings
42.42%
Success rate
34.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $32.71 | +141.52% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.86 | +115.05% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.63 | +59.92% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $20 → $22 | $0.59 | +3,641.50% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $10.90 | +6,505.50% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.43 | -65.03% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $11.45 | -12.66% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.80 | -28.57% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $10.75 | +2.33% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $27.49 | +45.51% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $32.79 | +86.03% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $94.60 | -4.86% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $5 | $4.92 | +1.63% | 4 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.90 | +144.90% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $9.77 | +1,190.32% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.82 | +2,337.24% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $26.40 | +150.00% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $0.79 | +3,696.51% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.98 | +452.76% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $4.12 | +409.71% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.64 | +1,241.46% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.52 | +1,413.16% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $16.27 | +29.07% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.81 | +3,463.09% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.34 | +4,377.61% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $56.09 | -71.47% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $40.65 | -33.58% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.18 | +13,383.15% | 1 | May 26, 2020 |
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $32.71
Upside: +141.52%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.86
Upside: +115.05%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.63
Upside: +59.92%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $20 → $22
Current: $0.59
Upside: +3,641.50%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $10.90
Upside: +6,505.50%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.43
Upside: -65.03%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $11.45
Upside: -12.66%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.80
Upside: -28.57%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $10.75
Upside: +2.33%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $27.49
Upside: +45.51%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $32.79
Upside: +86.03%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $94.60
Upside: -4.86%
Mar 2, 2022
Upgrades: Buy
Price Target: $1 → $5
Current: $4.92
Upside: +1.63%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.90
Upside: +144.90%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $9.77
Upside: +1,190.32%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.82
Upside: +2,337.24%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $26.40
Upside: +150.00%
Aug 24, 2021
Initiates: Buy
Price Target: $30
Current: $0.79
Upside: +3,696.51%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $3.98
Upside: +452.76%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $4.12
Upside: +409.71%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.64
Upside: +1,241.46%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.52
Upside: +1,413.16%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $16.27
Upside: +29.07%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.81
Upside: +3,463.09%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.34
Upside: +4,377.61%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $56.09
Upside: -71.47%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $40.65
Upside: -33.58%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.18
Upside: +13,383.15%